Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 85

Results For "EY"

3993 News Found

Galimedix completes phase 1 study with oral small molecule GAL-101
Biotech | September 16, 2025

Galimedix completes phase 1 study with oral small molecule GAL-101

The study further confirmed that GAL-101 effectively crosses the blood-brain barrier


Biocartis receives FDA approval for Idylla CDx MSI test
News | September 16, 2025

Biocartis receives FDA approval for Idylla CDx MSI test

First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States


Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India
News | September 16, 2025

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India

Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB


Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule
News | September 16, 2025

Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule

Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders


AstraZeneca’s Phase III FLAURA2 trial shows positive result
News | September 15, 2025

AstraZeneca’s Phase III FLAURA2 trial shows positive result

Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial


Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
Drug Approval | September 15, 2025

Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis


Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr
News | September 13, 2025

Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr

AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool


Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing
Biotech | September 12, 2025

Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing

Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients


Shukra Pharmaceuticals inks distribution tie-up with Wockhardt
Supply Chain | September 12, 2025

Shukra Pharmaceuticals inks distribution tie-up with Wockhardt

The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)